XML 37 R24.htm IDEA: XBRL DOCUMENT
v3.23.1

Note Q - Stock Options | 12 Months Ended
--- | ---
Dec. 31, 2022
Notes to Financial Statements |
Share-Based Payment Arrangement [Text Block] | NOTE Q—STOCK OPTIONS 2015 Stock Option Plan On January 27, 2016, the stockholders approved the 2015 Equity Incentive Plan (the “2015 Plan”). The 2015 Plan initially reserved 187,500 shares of common stock for issuance of options, restricted stock, and other equity based awards to employees, officers, directors, and consultants of the Company. In 2021, the stockholders approved an amendment to the 2015 to increase the shares of common stock authorized for issuance under the 2015 Plan from 187,500 shares to 789,000 shares together with other technical changes. The term of stock options granted under the 2015 Plan, may not exceed ten years, exercise prices may not be below 100-110% of fair market value, and vesting occurs over time periods set forth in written agreements with the recipients. In the event of a change in control, certain stock awards issued under the 2015 Plan may be subject to additional acceleration of vesting as may be provided in the participants’ written agreement. The 2015 Plan expires in December 2025. Non-Plan Stock Options Periodically, the Company has granted options outside of the 2015 Plan to various employees and consultants. In the event of change in control, as defined, certain of the non-plan options outstanding vest immediately. Stock Option Activity Information summarizing option activity is as follows:
|  | Number of Options |  |  | Weighted average |  |  | Weighted average remaining |  |  | Aggregate |
|  | 2015 Plan |  |  | Non Plan |  |  | Total |  |  | exercise price |  |  | life (in years) |  |  | intrinsic value |
Outstanding, as of December 31, 2020 |  |  | 94,183 |  |  |  | 133,091 |  |  |  | 227,274 |  |  | $ | 17.61 |  |  |  | 3.87 |  |  | $ | 0 |
Granted |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Exercised |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Forfeited |  |  | (3,291 | ) |  |  | — |  |  |  | (3,291 | ) |  |  | 3.87 |  |  |  |  |  |  |  |  |
Expired |  |  | (84 | ) |  |  | (11,438 | ) |  |  | (11,522 | ) |  |  | 39.13 |  |  |  |  |  |  |  |  |
Outstanding, as of December 31, 2021 |  |  | 90,808 |  |  |  | 121,653 |  |  |  | 212,461 |  |  | $ | 16.65 |  |  |  | 3.03 |  |  | $ | 0 |
Granted |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Exercised |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Forfeited |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Expired |  |  | — |  |  |  | (9,465 | ) |  |  | (9,465 | ) |  |  | 17.28 |  |  |  |  |  |  |  |  |
Outstanding, as of December 31, 2022 |  |  | 90,808 |  |  |  | 112,188 |  |  |  | 202,996 |  |  | $ | 16.63 |  |  |  | 2.14 |  |  | $ | 0 |
Vested or expected to vest at December 31, 2022 |  |  |  |  |  |  |  |  |  |  | 201,271 |  |  | $ | 16.72 |  |  |  | 2.12 |  |  | $ | 0 |
Exercisable at December 31, 2022 |  |  |  |  |  |  |  |  |  |  | 194,561 |  |  | $ | 17.12 |  |  |  | 2.03 |  |  | $ | 0 |
The options outstanding and exercisable at December 31, 2022 were in the following exercise price ranges:
|  |  |  |  |  | Options Outstanding |  |  | Options Exercisable |
Range of exercise prices |  |  | Number of shares |  |  | Weighted average exercise price |  |  | Weighted average remaining life (in years) |  |  | Number exercisable |  |  | Weighted average exercise price |
$ | 4.08 | - | 5.84 |  |  |  | 25,565 |  |  | $ | 5.20 |  |  |  | 4.63 |  |  |  | 17,130 |  |  | $ | 5.20 |
$ | 5.85 | - | 28.00 |  |  |  | 177,431 |  |  |  | 18.27 |  |  |  | 1.81 |  |  |  | 177,431 |  |  |  | 18.27 |
$ | 4.08 | - | 28.00 |  |  |  | 202,996 |  |  |  |  |  |  |  |  |  |  |  | 194,561 |  |  |  |  |
The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $0.59, $2.21, and $3.52 as of December 31, 2022, 2021 and 2020, respectively, which would have been received by the option holders had all option holders exercised their options as of that date. There were no in-the-money options exercisable as of December 31, 2022, 2021 and 2020. The weighted average fair value of options granted during the years ended December 31, 2022 and 2021 was $0 as no options were granted in either year. The total intrinsic value of options exercised during the years ended December 31, 2022 and 2021 was $0 as no options were exercised in either year. The total fair value of shares vested during the years ended December 31, 2022 and 2021 was $100,668 and $252,874, respectively. As of December 31, 2022, future forfeiture adjusted compensation cost related to nonvested stock options is $17,630 and will be recognized over an estimated weighted average period of 0.64 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration